Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Capricor Therapeutics (CAPR) over the last 12 years, with Q3 2025 value amounting to $494725.0.

  • Capricor Therapeutics' Depreciation and Depletion rose 3697.96% to $494725.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 2984.58%. This contributed to the annual value of $1.4 million for FY2024, which is 3333.69% up from last year.
  • Capricor Therapeutics' Depreciation and Depletion amounted to $494725.0 in Q3 2025, which was up 3697.96% from $486278.0 recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Depreciation and Depletion registered a high of $494725.0 during Q3 2025, and its lowest value of $49054.0 during Q1 2021.
  • In the last 5 years, Capricor Therapeutics' Depreciation and Depletion had a median value of $254702.0 in 2023 and averaged $245116.4.
  • As far as peak fluctuations go, Capricor Therapeutics' Depreciation and Depletion skyrocketed by 14878.47% in 2023, and later surged by 2213.76% in 2024.
  • Quarter analysis of 5 years shows Capricor Therapeutics' Depreciation and Depletion stood at $78645.0 in 2021, then soared by 143.63% to $191602.0 in 2022, then soared by 60.55% to $307608.0 in 2023, then grew by 22.14% to $375705.0 in 2024, then skyrocketed by 31.68% to $494725.0 in 2025.
  • Its Depreciation and Depletion was $494725.0 in Q3 2025, compared to $486278.0 in Q2 2025 and $405450.0 in Q1 2025.